Hospital admissions · Adults with acute asthma
Combination inhaled therapy probably leads to lower hospitalisation compared with SABA alone (moderate certainty).
1 finding from 1 review
Total adverse events · Adults with acute asthma
Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).
1 finding from 1 review
FEV1 · Adults with acute asthma
1 finding from 1 review
Percent change FEV₁(%) · Adults with acute asthma
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · Adults with acute asthma
1 finding from 1 review
Change in PEF · Adults with acute asthma
1 finding from 1 review
Relapse · Adults with acute asthma
Combination inhaled therapy probably leads to lower relapse rates compared with SABA alone (moderate certainty).
1 finding from 1 review
Hospital admissions · children with acute asthma
Multiple treatment of beta₂‐agonist via spacer (chamber) showed no clear difference in hospital admission compared with nebuliser (low certainty).
1 finding from 1 review
Tremor · Adults with acute asthma
Multiple treatment of beta₂‐agonist via spacer (chamber) showed no clear difference in number of participants developing tremor compared with nebuliser (moderate certainty).
1 finding from 1 review
Duration in emergency department (minutes) · children with acute asthma
1 finding from 1 review
Final rise in FEV₁ (% predicted) · children with acute asthma
1 finding from 1 review
Rise in pulse rate (% baseline) · children with acute asthma
1 finding from 1 review
Tremor · children with acute asthma
Multiple treatment of beta₂‐agonist via spacer (chamber) probably leads to lower number of participants developing tremor compared with nebuliser (moderate certainty).
1 finding from 1 review
Hospital admissions · Adults with acute asthma
Multiple treatment of beta₂‐agonist via spacer (chamber) showed no clear difference in hospital admission compared with nebuliser (moderate certainty).
1 finding from 1 review
Duration in emergency department (minutes) · Adults with acute asthma
1 finding from 1 review
Final rise in FEV₁ (% predicted) · Adults with acute asthma
1 finding from 1 review
Rise in pulse rate (% baseline) · Adults with acute asthma
1 finding from 1 review
Exacerbations needing hospitalisation · people with asthma
Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · people with asthma
Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review